Technical Analysis for GTXI - GTx, Inc.

Grade Last Price % Change Price Change
grade F 1.03 -2.83% -0.03
GTXI closed down 2.83 percent on Friday, May 17, 2019, on 18 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Earnings due: May 21

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical GTXI trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Bollinger Band Squeeze Range Contraction -2.83%
Lower Bollinger Band Walk Weakness -2.83%
BB Squeeze + Lower Band Touch Range Contraction -2.83%

Older signals for GTXI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. It is involved in developing Enobosarm, an androgen receptor modulator, which is in Phase III clinical trials for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer in the United States, Europe, Russia, and South America. The company also develops Capesaris, an oral nonsteroidal estrogen receptor alpha agonist that is in Phase II clinical trial for secondary hormonal therapy in men with metastatic castration resistant prostate cancer. In addition, its preclinical development stage products include inhibitors of steroid biosynthetic enzymes, anticancer therapies, estrogen receptor beta agonists, and other novel compounds for the potential treatment of cancer, metabolic diseases, ophthalmic diseases, psoriasis, and pain. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Chemistry Biopharmaceutical Cancer Pain Treatment Of Cancer Endocrine System Non Small Cell Lung Cancer Organic Chemistry Psoriasis Alcohols Metabolic Diseases Hepatotoxins Metastatic Castration Resistant Prostate Cancer Androgen Receptor Anticancer Therapies Estrogens Ophthalmic Diseases
Is GTXI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.6
52 Week Low 0.74
Average Volume 321,615
200-Day Moving Average 4.6872
50-Day Moving Average 1.1958
20-Day Moving Average 1.1145
10-Day Moving Average 1.099
Average True Range 0.0719
ADX 23.0
+DI 10.1899
-DI 19.0675
Chandelier Exit (Long, 3 ATRs ) 0.9843
Chandelier Exit (Short, 3 ATRs ) 1.2157
Upper Bollinger Band 1.1978
Lower Bollinger Band 1.0312
Percent B (%b) -0.01
BandWidth 14.948407
MACD Line -0.0337
MACD Signal Line -0.0246
MACD Histogram -0.0091
Fundamentals Value
Market Cap 16.54 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -0.60
Price-to-Sales 0.00
Price-to-Book 14.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.09
Resistance 3 (R3) 1.10 1.08 1.08
Resistance 2 (R2) 1.08 1.07 1.08 1.08
Resistance 1 (R1) 1.06 1.06 1.05 1.05 1.07
Pivot Point 1.04 1.04 1.04 1.04 1.04
Support 1 (S1) 1.02 1.03 1.01 1.01 0.99
Support 2 (S2) 1.00 1.02 1.00 0.98
Support 3 (S3) 0.98 1.00 0.98
Support 4 (S4) 0.97